

Piro Lito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8232550/publications.pdf>

Version: 2024-02-01

25
papers

5,602
citations

394421

19
h-index

580821

25
g-index

25
all docs

25
docs citations

25
times ranked

7584
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. JTO Clinical and Research Reports, 2022, 3, 100256.	1.1	4
2	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. British Journal of Cancer, 2022, 126, 889-898.	6.4	8
3	Expanding the Arsenal of Clinically Active <i>KRAS</i> G12C Inhibitors. Journal of Clinical Oncology, 2022, 40, 2609-2611.	1.6	4
4	Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors. Cancer Discovery, 2021, 11, 17-19.	9.4	9
5	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12Câ€“Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2209-2215.	7.0	65
6	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 2604-2612.	7.0	20
7	Acquired Resistance to KRAS ^{G12C} Inhibition in Cancer. New England Journal of Medicine, 2021, 384, 2382-2393.	27.0	482
8	The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Science, 2021, 374, 197-201.	12.6	35
9	Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature, 2021, 599, 679-683.	27.8	183
10	The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2020, 10, 54-71.	9.4	820
11	Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature, 2020, 577, 421-425.	27.8	321
12	Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Cell, 2020, 183, 850-859.	28.9	128
13	KRAS ^{G12C} Inhibition with Sotorasib in Advanced Solid Tumors. New England Journal of Medicine, 2020, 383, 1207-1217.	27.0	1,049
14	Quest for Clinically Effective RAF Dimer Inhibitors. Journal of Clinical Oncology, 2020, 38, 2197-2200.	1.6	5
15	Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. Clinical Cancer Research, 2019, 25, 7202-7217.	7.0	29
16	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 334-340.	7.0	323
17	A treatment strategy for KRAS-driven tumors. Nature Medicine, 2018, 24, 902-904.	30.7	34
18	Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required. Clinical Cancer Research, 2017, 23, 1365-1367.	7.0	1

#	ARTICLE	IF	CITATIONS
19	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. Nature Medicine, 2017, 23, 929-937.	30.7	146
20	Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science, 2016, 351, 604-608.	12.6	499
21	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer, 2016, 17, e121-e129.	2.6	116
22	Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors. Cancer Cell, 2014, 25, 697-710.	16.8	238
23	Hematopoietic Stem Cell Origin of <i>BRAF</i> V600E Mutations in Hairy Cell Leukemia. Science Translational Medicine, 2014, 6, 238ra71.	12.4	102
24	Tumor adaptation and resistance to RAF inhibitors. Nature Medicine, 2013, 19, 1401-1409.	30.7	512
25	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. Cancer Cell, 2012, 22, 668-682.	16.8	469